Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Net Cash Flow (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed Net Cash Flow for 7 consecutive years, with $168.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow rose 1438.59% to $168.5 million in Q4 2025 year-over-year; TTM through Nov 2025 was $137.0 million, a 147.48% increase, with the full-year FY2025 number at $137.0 million, up 147.48% from a year prior.
  • Net Cash Flow was $168.5 million for Q4 2025 at Nurix Therapeutics, up from -$5.8 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $168.5 million in Q4 2025 to a low of -$66.9 million in Q4 2021.
  • A 5-year average of $6.4 million and a median of $2.5 million in 2022 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: crashed 2681.55% in 2023, then soared 1438.59% in 2025.
  • Nurix Therapeutics' Net Cash Flow stood at -$66.9 million in 2021, then surged by 125.28% to $16.9 million in 2022, then dropped by 27.16% to $12.3 million in 2023, then decreased by 11.12% to $11.0 million in 2024, then skyrocketed by 1438.59% to $168.5 million in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Net Cash Flow are $168.5 million (Q4 2025), -$5.8 million (Q3 2025), and $8.3 million (Q2 2025).